Chris Karlovich,
Associate Director, Molecular Diagnostics
Chris Karlovich is an Associate Director of Molecular Diagnostics at Clovis Oncology. He provides scientific and operational oversight over molecular diagnostics and companion diagnostic development for rociletinib (CO-1686), a mutant-selective inhibitor of EGFR in clinical trials for NSCLC. Prior to coming to Clovis, Dr. Karlovich spent nine years in the diagnostics industry in the areas of biomarker discovery and in vitro diagnostic (IVD) test development for companion diagnostics.
|
|
|
